Companies are profiled across 10 distinct signals. Ask any complex question — requirement, solicitation, patent — and get a prioritized, evidence-backed shortlist.
Bring a requirement, a solicitation, a patent portfolio, or a plain question. Get back a ranked shortlist, with an evidence-backed justification memo for each company.
A requirement, a solicitation, a patent portfolio, or a plain question — extract what's actually being asked.
Match the question against every canonical company profile — not a keyword index.
Return a ranked shortlist with an evidence-backed justification memo for each company.
Unknown firms are surfaced, resolved, and onboarded — the next search starts from a bigger universe.
Three real searches, open to everyone. Explore every company and the reasoning behind each match, then run your own.
Matches suppliers against five requirements, from vacuum performance to ruggedization and field sterilization.
Licensing sources and partners for a nucleic-acid lateral flow platform, ranked by patent position.
Established and contract manufacturers with lateral flow production capacity and technology-transfer experience.
Start from a solicitation or from a patent. Either way, Hoover searches the same resolved company profiles.
Read a solicitation, extract the required capabilities, and return the companies that meet them.
Identify companies that meet targeted membership criteria for your organization
Assemble complementary teams by matching partners whose capabilities fill each other's gaps.
Find out-licensing targets (who needs this IP) and in-licensing sources (who owns IP you need).
Identify partners with complementary technology.
One firm shows up as a parent, a dozen subsidiaries, an IP-holding arm, and a pile of misspelled patent assignees. Until that's resolved, every search is counting the same company four times and missing it twice.
Hoover resolves the signals — patents, products, publications, clinical trials, FDA clearances — to the companies behind them, and holds each as a single canonical profile carrying that company's expertise, capabilities, and technologies. Search runs against the resolved graph, not a keyword index, so a question phrased in your terms finds companies described in theirs.
An asset that is slow and costly to assemble, and compounds as each new source is added.
Built on the same graph: every technology class, the patents behind it and the companies building it. Read the full report free.
Which lateral flow technologies beyond standard antigen tests are on the market, how they compare on sensitivity, cold chain and time to result, and which can be produced close to where they’re needed.
Want this on your market? Request a custom report
Three academic institutions hold 85 of 193 CRISPR-Cas lateral flow patents.
Patents held, CRISPR-Cas lateral flow class. Blue: academic. Gray: leading commercial holder.
Nanobody and aptamer tests promise better heat stability, but none are FDA-cleared and field data under austere conditions doesn’t exist yet.
CRISPR-Cas tests are 100–1,000× more sensitive than standard lateral flow, at the cost of 30–60 minute multi-step workflows.
Foundational nanobody and aptamer patents have expired, while CRISPR diagnostics may need licences from three to five holders.
Everything above, without seat maths or usage tiers. Cancel any time.
Bring a requirement, a portfolio, or a question you can't answer with a keyword search — and see the shortlist with the reasoning behind every name on it.